4-(benzyloxy)-3-bromobenzonitrile | 317358-76-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(benzyloxy)-3-bromobenzonitrile
• 英文别名: 4-benzyloxy-3-bromobenzonitrile；3-bromo-4-[(phenylmethyl)oxy]benzonitrile；3-Bromo-4-(phenylmethoxy)-benzonitrile；3-bromo-4-phenylmethoxybenzonitrile
• CAS: 317358-76-2
• 化学式: C₁₄H₁₀BrNO
• mdl: MFCD09709331
• 分子量: 288.143
• InChiKey: QQOOGFABDFSRFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(benzyloxy)-3-bromobenzonitrile 在 palladium 10% on activated carbon 氢气 、 zinc(II) chloride 作用下， 以 四氢呋喃 、 乙醇 、 乙酸乙酯 为溶剂， 反应 0.5h， 生成 3-ethyl-4-hydroxybenzonitrile
  参考文献：
  名称：

  [EN] IMIDAZOLIDINEDIONE DERIVATIVES
  [FR] DÉRIVÉS D'IMIDAZOLIDINEDIONE

  摘要：

  这项发明提供了化合物(Ia)及其药学上可接受的盐。该发明还提供了将这些化合物或盐用作Kv3.1和/或Kv3.2的调节剂，以及在需要Kv3.1和/或Kv3.2调节剂的疾病或紊乱的治疗中的用途，如抑郁症和情绪障碍、听觉障碍、精神分裂症、物质滥用障碍、睡眠障碍或癫痫病。

  公开号：

  WO2011069951A1
• 作为产物：
  描述：

  4-(苄氧基)-3-溴苯甲醛 在 吡啶 、 盐酸羟胺 、 乙酸酐 作用下， 反应 4.0h， 以91%的产率得到4-(benzyloxy)-3-bromobenzonitrile
  参考文献：
  名称：

  Synthesis of benzyloxycyanophenylboronic esters

  摘要：

  The synthesis of six new benzyloxycyanoboronic esters: 2-benzyloxy-6-cyanophenyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (4a), 4-benzyloxy-2-cyanophenyl-4,4,5, 5-tetramethyl-[1,3,2]dioxaborolane (4b), 4-benzyloxy-3-cyanophenyl-4,4,5,5-tetramethyl-[1,3,2] dioxaborolane (8a), 2-benzyloxy-5-cyanophenyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (8b), 3-benzyloxy-4-cyanophenyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (12a), and 2-benzyloxy-5-cyanophenyl-4,4,5,5-tetramethyl-[1,3,2] dioxaborolane (12b) is reported.

  DOI：

  10.1515/hc.2011.001

文献信息

• [EN] COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE<br/>[FR] COMPOSÉS PRÉSENTANT UNE ACTIVITÉ AU NIVEAU DU RÉCEPTEUR M1 ET LEURS UTILISATIONS EN MÉDECINE
  申请人：GLAXO GROUP LTD

  公开号：WO2009037294A1

  公开（公告）日：2009-03-26

  Compounds of formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.

  提供具有公式(I)或其盐的化合物：其中R4、R5、R6、Q、A、Y和R按描述定义。披露了这些化合物作为药物的使用和在制造用于治疗精神病性障碍、认知障碍和阿尔茨海默病药物中的应用。本发明还公开了包含这些化合物的药物组合物。
• Chemical compounds
  申请人：——

  公开号：US20030187020A1

  公开（公告）日：2003-10-02

  Provided herein are novel and useful compounds having a tryptase inhibition activity, pharmaceutical compositions comprising such compounds, and methods treating subjects suffering from a condition, disease, or disorder that can be ameliorated by the administration of an inhibitor of tryptase, e.g., asthma and inflammatory diseases, to name only a few.

  本文提供了具有胰蛋白酶抑制活性的新颖和有用化合物，包括含有这些化合物的药物组合物，以及治疗患有可以通过给予胰蛋白酶抑制剂（例如哮喘和炎症性疾病等）而得到改善的疾病、疾病或紊乱的方法。
• VLA-4 inhibitor compounds
  申请人：Daiichi Pharmaceutical Co., LTD.

  公开号：US20030078249A1

  公开（公告）日：2003-04-24

  Compounds that selectively inhibit the binding of ligands to &agr;4&bgr;1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: 1 As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are pharmaceutical compositions, methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion, which involve compounds of Formula I.

  本发明公开了选择性抑制配体与α4β1整合素（VLA-4）结合的化合物及其制备方法。在一个实施例中，本发明的化合物由式I表示： 1 作为VLA-4介导的细胞粘附的选择性抑制剂，本发明的化合物可用于治疗与该粘附相关的疾病，包括但不限于炎症和自身免疫反应、糖尿病、哮喘、银屑病、炎症性肠病、移植排斥和肿瘤转移。还公开了包含式I化合物的药物组合物、抑制VLA-4介导的细胞粘附的方法以及治疗与VLA-4介导的细胞粘附相关疾病的方法。
• Progress toward the total synthesis of 9β-hydroxyvertine: Construction of an advanced quinolizidine intermediate
  作者：Thanaphat Thaima、Anthony C. Willis、Stephen G. Pyne

  DOI：10.1016/j.tet.2019.130476

  日期：2019.9

  Progress toward the total synthesis of 9β-hydroxyvertine 2 is described. Our approach involves a Petasis borono-Mannich reaction to assemble a key intermediate A, securing the correct configuration at H-9 and H-10 in the final targeted molecule. Subsequent formation of the quinolizidine framework B allowed the synthesis of an advanced intermediate containing all but the lactone moiety of 2. Our unsuccessful

  描述了向9β-羟基vertine 2的全合成的进展。我们的方法涉及Petasis borono-Mannich反应，以组装关键中间体A，从而确保最终目标分子中H-9和H-10的正确构型。随后形成的喹唑烷骨架B允许合成包含除2的内酯部分以外的所有部分的高级中间体。还介绍了我们引入这种内酯功能的失败尝试。
• CONDENSED HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20170349605A1

  公开（公告）日：2017-12-07

  The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification].

  本发明涉及一种具有肠肽酶抑制作用的缩合杂环化合物，可用于治疗或预防肥胖、糖尿病等疾病，以及含有该化合物的药物。具体而言，本发明涉及以下式（I）所代表的化合物或其盐，以及含有该化合物的药物[在式中，每个符号如规范中定义]。